TVTX250516P12500
- 0.00
- 0.000.00%
Travere Therapeutic Newsroom
Cantor Fitzgerald Maintains Travere Therapeutic(TVTX.US) With Buy Rating
Cantor Fitzgerald Maintains Travere Therapeutic(TVTX.US) With Buy Rating
Travere Therapeutics Analyst Ratings
Scotiabank Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Cuts Target Price to $30
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $47
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $47
Cantor Fitzgerald Maintains Travere Therapeutic(TVTX.US) With Buy Rating
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $31
Travere Therapeutics Is Maintained at Buy by B of A Securities
Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $44
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Announces Target Price $22
Travere Therapeutics Is Maintained at Buy by Citigroup
Citi Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $35
Travere Therapeutics Analyst Ratings
Scotiabank Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $32
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $29
TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $30
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $47